High-Grade Non-Muscle Invasive Bladder Cancer: When to Move to Early Radical Cystectomy?
bladder cancer
nonmuscle invasive
radical cystectomy
survival
transurethral resection
urothelial malignancy
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
accepted:
09
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Objectives To compare the outcomes of bladder preservation therapy with early or deferred radical cystectomy (RC) in high-grade non-muscle invasive bladder cancer. Methods Prospectively collected data were obtained for patients undergoing transurethral resection of bladder tumor (TURBT) at a tertiary care center between 2007 and 2018. Patients with a high-grade tumor (HGT1) were divided into three groups, depending on the treatment plan: conservative (GI), early RC (GII), or deferred RC (GIII). Kaplan-Meier analysis was performed to assess the cancer-specific survival (CSS). Results Seventy-one patients were included, and the patients had a median (range) age of 49 (32-72) years. The GI, GII, and GIII groups included 34 (47.9%), 14 (19.7%), and 23 (32.4%) patients, respectively. A significantly lower number of GII patients underwent >2 TURBTs (14.3% vs. 100%, p<0.001). Compared to GIII patients, GII patients had a shorter time to RC from the initial diagnosis (5.7 vs. 36.2 months, p=0.03). Ileal conduit and orthotropic bladder diversions were comparable between both groups, with significantly higher postoperative complications in GIII patients. The median (IQR) follow-up times for the groups were 84 (49-102), 82 (52-112), and 73 (36-89) months, respectively. The five-year and 10-year CSS for GII and GIII patients was 79% vs. 75% and 78% vs. 64%, respectively (log rank=0.19). Conclusion Early RC should be considered an alternative treatment option in selected patients with HGT1 BC with expected longer life expectancy, which may significantly decrease postoperative complications and improve the CSS. However, selection bias in the current retrospective study may influence these outcomes.
Identifiants
pubmed: 34926001
doi: 10.7759/cureus.19399
pmc: PMC8656290
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e19399Informations de copyright
Copyright © 2021, Azhar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Urol. 2018 Mar;199(3):663-668
pubmed: 28859892
BJU Int. 2005 Feb;95(3):301-5
pubmed: 15679782
J Urol. 2000 Jun;163(6):1697-701
pubmed: 10799163
Urol Ann. 2011 Sep;3(3):127-32
pubmed: 21976924
BJU Int. 2011 Oct;108(8 Pt 2):E284-8
pubmed: 21244611
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
J Urol. 1998 Oct;160(4):1285-90
pubmed: 9751337
Eur Urol. 2016 Jan;69(1):60-9
pubmed: 26210894
Urology. 2005 Nov;66(5):917-22
pubmed: 16286095
Eur Urol. 2010 Feb;57(2):300-9
pubmed: 19766384
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
BJU Int. 2014 Jun;113(6):894-9
pubmed: 24053444
Can Urol Assoc J. 2010 Feb;4(1):56-64
pubmed: 20165581
Urol Oncol. 2013 Aug;31(6):866-70
pubmed: 21906968
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Int J Urol. 2018 Jan;25(1):18-24
pubmed: 28741703
Arch Esp Urol. 2013 Dec;66(10):967-9
pubmed: 24369191
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
J Urol. 2008 Jan;179(1):53-6
pubmed: 17997439
Eur Urol. 2018 Nov;74(5):597-608
pubmed: 30017405
World J Urol. 2009 Jun;27(3):347-51
pubmed: 19319539
J Urol. 2002 Apr;167(4):1573-83
pubmed: 11912367
J Clin Oncol. 2015 Feb 20;33(6):643-50
pubmed: 25559810
World J Surg Oncol. 2018 Oct 2;16(1):197
pubmed: 30285788
Eur Urol. 2011 Sep;60(3):493-500
pubmed: 21664041